The Analyst Verdict: Globus Medical In The Eyes Of 6 Experts
Portfolio Pulse from Benzinga Insights
Six analysts have recently updated their ratings on Globus Medical (NYSE:GMED), with a mix of bullish, somewhat bullish, and indifferent stances. The average 12-month price target is now $63.33, up from $59.50, with individual targets ranging from $53.00 to $75.00. Analyst actions include maintaining, raising, and lowering ratings and price targets. Globus Medical, a medical device company, has shown a significant revenue growth rate of 50.95% as of September 30, 2023, but has below-average net margin and ROE/ROA compared to the industry. The company's debt-to-equity ratio is healthy at 0.12.
January 11, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have mixed views on Globus Medical, with an updated average price target of $63.33, indicating a potential upside. The company's strong revenue growth is a positive sign, but profitability and return metrics are below industry averages.
The updated analyst ratings and increased price target suggest a positive outlook for GMED, which could lead to a short-term price increase. However, the below-average profitability and return metrics may temper investor enthusiasm, hence the score is not at the maximum bullish level.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100